蛋白 E7, HPV16 (His)

HPV16 E7 is a viral phosphoprotein with oncogenic activity, belonging to the human papillomavirus early protein family. HPV16 E7 activates the cell cycle by releasing E2F through proteasome degradation of pRB. HPV16 E7 can cooperate with E6 to immortalize cells and neutralize the toxicity of E5, while activating the AP-1/NF-κB pathway and downregulating E-cadherin to enhance migration and invasion, making it a core target for cervical cancer. Protein E7, HPV (His) is a recombinant HPV E7 protein expressed from E. coli with an N-6*His tag.

HPV16 E7 是一种多功能核磷蛋白，是 HPV16 致癌的关键癌蛋白，属于人乳头瘤病毒早期蛋白家族。HPV16 E7 的 C 端半区含有两个保守的 Cys-X-X-Cys 基序，能够可逆结合 Zn²⁺ 和 Cd²⁺，显著增加 α-螺旋含量，稳定蛋白疏水核心。HPV16 E7 的氨基端与腺病毒 E1A 蛋白存在序列相似性，并与 SV40 大 T 抗原有功能共性^[1][2]。
HPV16 E7 与视网膜母细胞瘤蛋白 (pRB) 高亲和力结合，通过蛋白酶体途径促进其降解，释放转录因子 E2F 以激活细胞周期进程。HPV16 E7 与 Ras 致癌基因协同作用，转化啮齿类动物的原代细胞。HPV16 E7 还与 E6 协同作用使原代人角质形成细胞永生化，并中和 E5 的细胞毒性效应。
HPV16 E7 通过激活 AP-1 和 NF-κB 通路，下调 E-钙粘蛋白表达，增强细胞迁移与侵袭能力。HPV16 E7 还通过干扰细胞间连接和细胞骨架重排，破坏细胞粘附，促进上皮-间质转化。HPV16 E7 的上游调控因子包括病毒启动子 (如 LCR) ；下游靶点包括 pRB、E2F、p16 及 E-钙粘蛋白等，可影响细胞周期控制和粘附分子表达。
HPV16 E7 可用于宫颈癌发生发展的作用机制。而全长 E7 蛋白或 E7 展示载体 (如干酪乳杆菌) 在 TC-1 小鼠等动物模型中诱导特异性抗肿瘤免疫，抑制肿瘤生长并提高生存率。HPV16 E7 是 HPV 相关癌症治疗性疫苗的主要靶点。

Protein E7, HPV (3 μg 质粒；48 h) 在滋养层和宫颈细胞系中与 E6 共表达时促进细胞生长并中和 E5 诱导的细胞毒性，降低细胞对组织培养塑料和子宫内膜细胞的粘附，激活 AP-1 和 NF-κB 通路，下调 E-钙粘蛋白表达，^[2]。
Protein E7, HPV (3 μg 质粒；24 h) 在滋养层细胞中与 E6 共表达时增强细胞迁移和侵袭能力^[2]。
Protein E7, HPV 在 CTL 测定中显示来自 E7 免疫小鼠的 T 细胞诱导 TC-1 细胞的特异性裂解^[3]。

Protein E7, HPV (1.5 nmol；皮下和腹腔注射；两次；首次免疫用完全弗氏佐剂 (CFA)，两周后用不完全弗氏佐剂 (IFA) 加强) 抑制小鼠中 TC-1 肿瘤生长，免疫小鼠中未检测到肿瘤，且在高剂量 TC-1 细胞挑战后仍保持无瘤生存，证明具有特异性保护免疫^[3]。
Protein E7, HPV (1.5 nmol；皮下注射；两次) 减少 E7 免疫小鼠的 T 细胞在被动免疫转移中引起的 TC-1 肿瘤生长，对血清无显著作用^[3]。
Protein E7, HPV (5×10⁹ CFU L. casei-PgsA-E7；口服；三个周期：第 0-4天、7-11天、21-25天) 诱导小鼠中 E7 特异性血清 IgG 和黏膜 IgA，增强细胞免疫，减小肿瘤体积，并在 TC-1 肿瘤挑战中提高生存率^[4]。

Measured by its binding ability in a functional ELISA. Immobilized Protein E7 at 10 μg/mL (100 μL/well) can bind Biotinylated MYC. The ED₅₀ for this effect is ≤0.3071 μg/mL.

• 
  Measured by its binding ability in a functional ELISA. Immobilized Protein E7 at 10 μg/mL (100 μL/well) can bind Biotinylated MYC. The ED₅₀ for this effect is 0.2398 μg/mL, corresponding to a specific activity is 4.17×10³ Unit/mg.

Virus

E. coli

N-6*His

P03129 (M1-P98)

1489079  [NCBI]

Full Length

MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP

Approximately 18-21 kDa

• 
  Greater than 94% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized from 0.22 μm filtered solution in 20 mM Tris-HCl, 0.5 M NaCl, 6% Trehalose, pH 8.0 or 50 mM Tris-HCl, 300 mM NaCl, pH 7.4 or PBS, 6% Trehalose, pH 7.4 or 50 mM Tris-HCl, 200 mM NaCl, pH 8.0 or 50 mM Tris-HCl, 300 mM NaCl, pH 7.4, 8% trehalose.
Note: For SPR assay, please replace the buffer. Primary amine components (e.g., Tris, imidazole) can affect protein-coupled chips.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Pahel G, et al. Structural and functional characterization of the HPV16 E7 protein expressed in bacteria. J Biol Chem. 1993 Dec 5;268(34):26018-25.  [Content Brief]

  [2]. Boulenouar S, et al. Effects of HPV-16 E5, E6 and E7 proteins on survival, adhesion, migration and invasion of trophoblastic cells. Carcinogenesis. 2010 Mar;31(3):473-80.  [Content Brief]

  [3]. Li YL, et al. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors. Oncol Rep. 2010 Nov;24(5):1323-9.  [Content Brief]

  [4]. Poo H, et al. Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice. Int J Cancer. 2006 Oct 1;119(7):1702-9.  [Content Brief]